Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Chamberlain

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Cancer|April 25, 2003
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomasMichael Glantz, Marc Chamberlain, Qin Liu, et al.
Frontiers in Oncology|June 25, 2025
Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven reviewRick Fontenot, Neha Biyani, Kishor Bhatia, et al.
Expert Review of Neurotherapeutics|June 1, 2006
Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphomaMyke R Green, Sajeel Chowdhary, Kristina M Lombardi, et al.
Journal of Neuro-Oncology|July 27, 2012
A prospective phase II single-institution trial of sunitinib for recurrent malignant gliomaEdward Pan, Daohai Yu, Binglin Yue, et al.
The Lancet. Oncology|May 29, 2018
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b studyRashmi Murthy, Virginia F Borges, Alison Conlin, et al.
Journal of Neuro-Oncology|November 16, 2016
Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastomaSurasak Phuphanich, Jeffrey Raizer, Marc Chamberlain, et al.
Journal of Neurosurgery|April 2, 2008
Patterns of care and outcomes among elderly individuals with primary malignant astrocytomaJill S Barnholtz-Sloan, Vonetta L Williams, John L Maldonado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trialStuart A Grossman, Xiaobu Ye, Marc Chamberlain, et al.
Neuro-Oncology|February 7, 2014
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO reviewThomas Kaley, Igor Barani, Marc Chamberlain, et al.
Investigational New Drugs|February 19, 2024
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinomaKathryn E Beckermann, Amita Patnaik, Ira Winer, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Cancer|April 25, 2003
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomasMichael Glantz, Marc Chamberlain, Qin Liu, et al.
Frontiers in Oncology|June 25, 2025
Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven reviewRick Fontenot, Neha Biyani, Kishor Bhatia, et al.
Expert Review of Neurotherapeutics|June 1, 2006
Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphomaMyke R Green, Sajeel Chowdhary, Kristina M Lombardi, et al.
Journal of Neuro-Oncology|July 27, 2012
A prospective phase II single-institution trial of sunitinib for recurrent malignant gliomaEdward Pan, Daohai Yu, Binglin Yue, et al.
The Lancet. Oncology|May 29, 2018
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b studyRashmi Murthy, Virginia F Borges, Alison Conlin, et al.
Journal of Neuro-Oncology|November 16, 2016
Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastomaSurasak Phuphanich, Jeffrey Raizer, Marc Chamberlain, et al.
Journal of Neurosurgery|April 2, 2008
Patterns of care and outcomes among elderly individuals with primary malignant astrocytomaJill S Barnholtz-Sloan, Vonetta L Williams, John L Maldonado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trialStuart A Grossman, Xiaobu Ye, Marc Chamberlain, et al.
Neuro-Oncology|February 7, 2014
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO reviewThomas Kaley, Igor Barani, Marc Chamberlain, et al.
Investigational New Drugs|February 19, 2024
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinomaKathryn E Beckermann, Amita Patnaik, Ira Winer, et al.
Pageof 4